Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy
Status:
Active, not recruiting
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
This is an single arm, open label, interventional phase II trial evaluating the efficacy of
umbilical cord blood (UCB) hematopoietic stem and progenitor cells (HSPC) expanded in culture
with stimulatory cytokines (SCF, Flt-3L, IL-6 and thromopoietin) on lympho-hematopoietic
recovery. Patients will receive a uniform myeloablative conditioning and post-transplant
immunoprophylaxis.